| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_90f4ee566d9768b969cde8b1de75ad0d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-193
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0789
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0787
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19 |
| filingDate |
2015-10-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_25de44305a78f969714cd460bc196869
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a600f0e408f04bb36b3d15e3834ec437 |
| publicationDate |
2016-03-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2016029088-A |
| titleOfInvention |
Treatment method using glycoPEGylated G-CSF |
| abstract |
Disclosed is a glycoPEGylated G-CSF with improved pharmacokinetic parameters and properties. The present invention is a therapeutically active glycoPEGylated G-CSF having improved pharmacokinetic parameters and properties compared to the same or very similar G-CSF peptide that is not glycoPEGylated. GlycoPEGylated G-CSF is provided. Furthermore, the present invention provides a method of mobilizing hematopoiesis in a subject, particularly a subject who has received or is to receive radiation or chemotherapy treatment. The methods and compositions of the invention can also be used to prevent, reduce and treat myelosuppressive effects in such treatments. [Selection] Figure 1 |
| priorityDate |
2007-04-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |